Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling (Q40095128)

17 September 2017

Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling (English)

1 reference

17 September 2017

M Beeram

1

1 reference

17 September 2017

Q-T N Tan

2

1 reference

17 September 2017

R R Tekmal

3

1 reference

17 September 2017

D Russell

4

1 reference

17 September 2017

A Middleton

5

1 reference

17 September 2017

L A DeGraffenried

6

1 reference

17 September 2017

1 August 2007

1 reference

17 September 2017

1 reference

17 September 2017

18

1 reference

17 September 2017

1323-1328

1 reference

17 September 2017

8

1 reference

The protein kinase B/Akt signalling pathway in human malignancy

17 September 2017

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDM170

Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDM170

Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDM170

Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDM170

Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDM170

AKT activation predicts outcome in breast cancer patients treated with tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDM170

The association between Akt activation and resistance to hormone therapy in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDM170

NF-kappa B inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDM170

Eicosapentaenoic acid restores tamoxifen sensitivity in breast cancer cells with high Akt activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDM170

Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDM170

Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDM170

Akt, a pleckstrin homology domain containing kinase, is activated primarily by phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDM170

Phosphorylation/cytoplasmic localization of p21Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDM170

Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDM170

Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDM170

Rapamycin potentiates transforming growth factor beta-induced growth arrest in nontransformed, oncogene-transformed, and human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDM170

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDM170

1 reference

17 September 2017

1 reference